Attendee search 

Dr. Laurent Audoly is Senior Vice President and heads Research and Development at Fabre Pharmaceuticals for both novel medicines and consumer healthcare products. Laurent is also Managing Partner and Founder of the Pierre Fabre Fund for Innovation. In addition, Laurent is president of the Orphan Diseases and the Medical Devices units within Pierre Fabre.
Prior to this role, Laurent was Chief Scientific Officer in biotech focused on next generation therapeutic proteins where he led the growth of the pipeline from no drug candidates prior to his arrival to a high value pipeline and multiple strategic partnerships with big pharma ultimately leading to a successful exit.
Laurent has held positions of increasing leadership responsibilities in the pharmaceutical industry (Pfizer, Merck, MedImmune) contributing to the identification of new projects and the development of five approved drugs in inflammation, dermatology, cardiovascular diseases, and oncology as well as leading large teams across the pharma value chain.
Throughout his career, he has championed high impact collaborations and established a world-wide network of academic and company-based partnerships. Many of these collaborations have resulted in drug development projects. Laurent is focused on strategic and business growth and has also established strong connections with internal and external commercial and manufacturing organizations. He studied medicine and chemistry for his Bachelor’s degree and graduated with a Ph.D. in Pharmacology from Vanderbilt University. Laurent was awarded a fellowship from the American Heart Association during his post-doctoral training at Duke University. Laurent has maintained strong ties with the academic world as an Associate Professor (Adj) at Duke NUS Graduate Medical School. He has also served on NIH study sections, given seminars at universities across the world, and published > 70 papers and patents. He is on the board and an advisor for multiple healthcare organizations across the world aimed at improving healthcare and accelerating the discovery and advancement of novel therapies for patients and their families.

Chris is a Managing Director at Torreya Partners, a leading global investment bank focused on facilitating partnerships, M&A transactions and financings in the pharmaceutical sector worldwide.  He joined Torreya from Sanofi Pasteur-MSD where he had responsibility for all business and corporate development activities.  He is also a Non-executive Director at Phico Therapeutics Ltd.

Prior to Sanofi Pasteur-MSD, Chris held positions at Astellas (Europe) in Business and Commercial Development and several years at Deloitte Corporate Finance where he headed up the Life Science Advisory practice assisting clients across the life science sector in a wide range of transactional activities (M&A, divestments, partnering, valuation, fund-raising).  Previously, Chris was at GlaxoSmithKline where he held roles of increasing responsibility in Business Development, Corporate Ventures and R&D.  He holds a PhD in Biochemistry and an MBA in Finance.

Pete Culpepper has spent 20 years in the financial field working for a wide range of companies and industries in the U.S. and abroad, especially high-growth startups. His experience with for-profit companies ranges from private start-ups to publicly traded, global conglomerates. He also has worked with large non-profits and a national CPA accounting firm. He led the national operating unit of a $1 billion publicly traded telecommunications company, as well as numerous operating units in Eastern Europe for a global telecommunications company. He handled the capital reporting process for a $5 billion global construction project and the formation of systems for a division that grew $150 million in revenue in two years. Previous employers include Neptec, Inc., a privately held optical networking component manufacturer; Metromedia Companies; and PageNet, the largest wireless messaging company in the world. Culpepper taught undergraduate and graduate business courses for the University of Phoenix Online. He is licensed as a Certified Public Accountant in Maryland and Tennessee. His professional affiliations include the American Institute of Certified Public Accountants, Financial Executives International and the Financial Executives Networking Group. Culpepper holds a master's of business administration (MBA) in finance from the University of Maryland. He earned an AAS in Accounting from the Northern Virginia Community College - Annandale, Virginia. He earned a bachelor's degree in philosophy from the College of William and Mary.

Coordinator, Asia & Europe

Exploring investors and health care industrys interest in Provectus

Luisa has been developing international teams for the last ten years and has been responsible for rolling out business-models in different sectors. Prior to that, she studied languages in Seville (ES), Bogotá (COL) and Mainz (GER). After finishing her studies, she worked for four years as Client Care Manager in Istanbul, Dubai and Johannesburg. Being based in Turkey, Luisa implemented the company’s European structure to the entire CEMEA area, while reporting to the HQ in Paris. For the last four years, she has been working as Senior Manager Business Development for the secure-cloud-provider Drooms and has been building up the life-science sector ever since.

Stephanie Léouzon is Partner and Head of Europe for Torreya Partners, a life sciences boutique advisory firm which she joined in 2012. Previously she worked in healthcare investment banking in the US and Europe from 1989 to 2010, most recently at Credit Suisse in London as a Managing Director and Senior Advisor.

She has advised life sciences clients on more than 25 strategic transactions, valued at over
$65 billion, and has been involved in over 45 financing transactions to provide over $10 billion to healthcare clients.

Stephanie earned an MBA degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a BA degree, cum laude, from Mount Holyoke College in 1985.

A CEO of major international biotech companies, as well as co-founder and shareholder of ABIVAX. An optimization expert in innovation cycle, from the early identification of molecules with a high potential for value creation who could benefit patients and shareholders in the long term, to their final release on the international market. A business valuation specialist of companies who hold a portfolio of innovative products, through their listing on a stock market or following their potential takeover. Executive partner of the Pierre Fabre Fund for Innovations.